U.S. markets closed
  • S&P Futures

    4,392.50
    +8.50 (+0.19%)
     
  • Dow Futures

    34,212.00
    +83.00 (+0.24%)
     
  • Nasdaq Futures

    15,191.50
    +28.00 (+0.18%)
     
  • Russell 2000 Futures

    2,219.50
    +4.60 (+0.21%)
     
  • Crude Oil

    72.03
    -0.20 (-0.28%)
     
  • Gold

    1,765.30
    -13.50 (-0.76%)
     
  • Silver

    22.65
    -0.26 (-1.14%)
     
  • EUR/USD

    1.1693
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0001 (-0.01%)
     
  • USD/JPY

    109.8460
    +0.0680 (+0.06%)
     
  • BTC-USD

    43,277.32
    +2,651.69 (+6.53%)
     
  • CMC Crypto 200

    1,088.58
    +48.10 (+4.62%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Globus Medical, Inc.'s (NYSE:GMED) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Globus Medical (NYSE:GMED) has had a great run on the share market with its stock up by a significant 20% over the last three months. We wonder if and what role the company's financials play in that price change as a company's long-term fundamentals usually dictate market outcomes. In this article, we decided to focus on Globus Medical's ROE.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.

Check out our latest analysis for Globus Medical

How Is ROE Calculated?

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Globus Medical is:

11% = US$184m ÷ US$1.6b (Based on the trailing twelve months to June 2021).

The 'return' is the income the business earned over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.11.

What Is The Relationship Between ROE And Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company’s earnings growth potential. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

Globus Medical's Earnings Growth And 11% ROE

At first glance, Globus Medical seems to have a decent ROE. Even when compared to the industry average of 11% the company's ROE looks quite decent. Despite the modest returns, Globus Medical's five year net income growth was quite low, averaging at only 4.1%. We reckon that a low growth, when returns are moderate could be the result of certain circumstances like low earnings retention or poor allocation of capital.

Next, on comparing with the industry net income growth, we found that Globus Medical's reported growth was lower than the industry growth of 14% in the same period, which is not something we like to see.

past-earnings-growth
past-earnings-growth

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Globus Medical's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.

Is Globus Medical Using Its Retained Earnings Effectively?

Conclusion

Overall, we feel that Globus Medical certainly does have some positive factors to consider. Although, we are disappointed to see a lack of growth in earnings even in spite of a high ROE and and a high reinvestment rate. We believe that there might be some outside factors that could be having a negative impact on the business. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.